Cabaletta Bio Q4 2022: cash $106.5M, CABA-201 IND expected H1 2023, data H1 2024

Cabaletta Bio, Inc.

R&D expenses $12.4M (Q4) and $39.3M (FY2022), up from $9.9M and $32.5M YoY.
Cash and investments $106.5M at Dec 31, 2022; funding expected into Q1 2025.
CABA-201 IND clearance expected H1 2023; initial clinical data anticipated H1 2024.
Raised $32.6M net in December 2022 public offering of pre-funded warrants and common stock.
DSG3-CAART combination sub-study data (1-month) expected H1 2023; MuSK-CAART trial initiated Nov 2022.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.5

Cabaletta Bio, Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2022.

Period: fourth quarter and fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 16, 2023, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the fourth quarter and fiscal year ended December 31, 2022.

View on SEC.gov

310 earnings releases filed in the last 30 days. Browse all earnings releases →

Cabaletta Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-071942

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.